Diagnostic for Discriminating Benign Mass From Ovarian Cancer and Application Thereof

摘要

Useful, accessible, and predictive biomarkers for discriminating between ovarian cancer and benign adnexal masses are provided. Specifically, peptide biomarkers present in bodily fluid samples such as cervical-vaginal fluid (CVF) have been identified as having particularly robust diagnostic for identifying whether ovarian masses such as adnexal masses are benign, and ruling our ovarian cancer. The biomarker peptides disclosed herein therefore provide significantly enhanced sensitivity and specificity levels relative to extant methods for distinguishing benign ovarian masses from ovarian cancers. The biomarkers provide a timely and cost-efficient diagnostic capable of being used in a selection process to identify patients for whom treatment, which may include surgical resection and/or monitoring, may be performed by an obstetric gynecologist rather than a gynecologic oncologist.